Prostate Cancer Stem Cells: The Role of CD133

Jianhui Yang; Omar Aljitawi; Peter Van Veldhuizen

doi:10.3390/cancers14215448

Cancers (Nov 2022)

Prostate Cancer Stem Cells: The Role of CD133

Jianhui Yang,
Omar Aljitawi,
Peter Van Veldhuizen

Affiliations

Jianhui Yang: Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
Omar Aljitawi: Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
Peter Van Veldhuizen: Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA

DOI: https://doi.org/10.3390/cancers14215448
Journal volume & issue: Vol. 14, no. 21
p. 5448

Abstract

Read online

Prostate cancer stem cells (PCSCs), possessing self-renewal properties and resistance to anticancer treatment, are possibly the leading cause of distant metastasis and treatment failure in prostate cancer (PC). CD133 is one of the most well-known and valuable cell surface markers of cancer stem cells (CSCs) in many cancers, including PC. In this article, we focus on reviewing the role of CD133 in PCSC. Any other main stem cell biomarkers in PCSC reported from key publications, as well as about vital research progress of CD133 in CSCs of different cancers, will be selectively reviewed to help us inform the main topic.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords